You are here

Rare Diseases

Rare Disease Biotechs Avrobio, Eidos Therapeutics File for IPOs

Rare Disease Biotechs Avrobio, Eidos Therapeutics File for IPOs

Xconomy

Eidos Therapeutics

Flag link:

GSK slims portfolio with sale of rare disease gene therapy drugs

GSK slims portfolio with sale of rare disease gene therapy drugs

Yahoo/Reuters

Orchard Therapeutics

Flag link:

Alexion buying Swedish biotech for $855 million to broaden rare disease pipeline

Alexion buying Swedish biotech for $855 million to broaden rare disease pipeline

Stat

WIlson Therapeutics

Flag link:

On Rare Disease Day, recognizing the life and work of biotech giant Henri A. Termeer

On Rare Disease Day, recognizing the life and work of biotech giant Henri A. Termeer

Endpoints

Rare Disease Day

Flag link:

Idera, Biocryst to merge, rebrand and focus in rare disease programs

Idera, Biocryst to merge, rebrand and focus in rare disease programs

Endpoints

Flag link:

Have PRVs Incentivized New Rare or Neglected Disease Research? Experts Discuss

Have PRVs Incentivized New Rare or Neglected Disease Research? Experts Discuss

RAPS.org

priority review vouchers

drug development

Flag link:

More efficient rare pediatric drug development: FDA drafts guidance

More efficient rare pediatric drug development: FDA drafts guidance

Endpoints

drug development

Flag link:

Alexion bolsters Soliris patent defense

Alexion bolsters Soliris patent defense

BioPharma Dive

Flag link:

5 Trends influencing drug pricing

5 Trends influencing drug pricing

BioPharma Dive

drug development

Flag link:

GlaxoSmithKline's talk of leaving rare diseases—amid slow Strimvelis sales—highlights challenges in the field

GlaxoSmithKline's talk of leaving rare diseases—amid slow Strimvelis sales—highlights challenges in the field

Fierce Pharma

Flag link:

FDA Reverses Decision, Allowing Amicus To File For Rare Disease Drug

FDA Reverses Decision, Allowing Amicus To File For Rare Disease Drug

Forbes

Amicus Therapeutics

Flag link:

Nearly every $100,000 drug approved in the last three years was for a rare disease

Nearly every $100,000 drug approved in the last three years was for a rare disease

Medical Marketing and Media

Flag link:

Tapping into the rare disease market

Tapping into the rare disease market

BioPharma Dive

Flag link:

Amicus CEO John Crowley, Not His Daughter Megan, Might Compel Trump to Make Big Changes at FDA

Amicus CEO John Crowley, Not His Daughter Megan, Might Compel Trump to Make Big Changes at FDA

TheStreet.com

Flag link:

Trump administration raises questions for rare-disease drugmakers

Trump administration raises questions for rare-disease drugmakers

Medical Marketing and Media

Affordable Care Act

Flag link:

FDA awards 21 grants to stimulate product development for rare diseases

FDA awards 21 grants to stimulate product development for rare diseases

FDA.gov

Flag link:

Horizon Buys Rare-Disease Company Raptor for $800 Million

Horizon Buys Rare-Disease Company Raptor for $800 Million

Bloomberg

Raptor Pharmaceutical

Flag link:

Shire PLC (ADR) May Now Seek Rare Disease Expansion With Raptor Pharmaceutical Corp.

Shire PLC (ADR) May Now Seek Rare Disease Expansion With Raptor Pharmaceutical Corp.

Bidness, ETC

Raptor Pharmaceuticals

Flag link:

FDA should listen to patients, not just clinical trial data, on rare disease therapies

FDA should listen to patients, not just clinical trial data, on rare disease therapies

Stat

orphan diseasese

Flag link:

Shire and Cincinnati Children's Hospital team up in rare diseases

Shire and Cincinnati Children's Hospital team up in rare diseases

Medical Marketing and Media

Flag link:

Pages